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We have previously reported that immunization of ponies with a baculovirus-expressed recombinant surface unit envelope
protein (rgp90) for equine infectious anemia virus (EIAV) resulted in enhancement of disease symptoms and virus replication
in 4 of 4 vaccine recipients subjected to a heterologous virus challenge (rgp90 I vaccine trial) (Wang et al., 1994). To extend
these studies of EIAV vaccine enhancement, two additional and independent rgp90 vaccine trials (rgp90 II and rgp90 III) were
performed. Combined, a total of 13 ponies were immunized with the rgp90 immunogen using our standard vaccination
procedures and challenged with a heterologous strain of EIAV. In contrast to the uniform enhancement observed in the rgp90
I vaccine trial, the severity of clinical symptoms varied markedly among the rgp90 recipients: 5 ponies experienced enhanced
disease symptoms, 5 ponies experienced moderate disease symptoms, and 3 ponies remained asymptomatic. Of particular
interest, in the 5 ponies with enhanced clinical symptoms was a severe thrombocytopenia (#105,000 platelets/ml) evident
coincident with the first febrile episode following virus challenge. Thrombocytopenia was either absent (7/10 ponies) or
substantially delayed (3/10 ponies) in naive control ponies inoculated with the standard EIAVPV challenge. Measurements of
virus replication in the challenged vaccine recipients indicated a correlation between the level of viral RNA in plasma and the
severity of the disease. Interestingly, an association was not observed between serum antibody reactivity to the vaccine or
native viral antigens and the frequency of enhancement. Thus, these observations demonstrate a previously unrecognized
complexity of rgp90 vaccine efficacy that has important implications for AIDS vaccine development. © 1998 Academic Press
INTRODUCTION
The identification of effective and safe methods to
protect susceptible hosts against lentivirus infection or
disease through immunization remains a high priority in
human and veterinary medicine. Although several ap-
proaches seem promising, none has been uniformly suc-
cessful in reaching the ideal goal, i.e., sterile protection
against challenge with any strain of the virus at doses
expected through every possible natural route of expo-
sure. Experimental immunizations with whole inactivated
equine infectious anemia virus (EIAV) or viral/recombi-
nant subunits of EIAV have provided evidence for a range
of possible responses to virus challenge. At one end of
the spectrum, sterile protection against homologous vi-
rus challenge with 104.5 median equid infectious doses
has been reported when the immunogen was inactivated
whole virus (Issel et al., 1992). At the other end of the
spectrum, immune enhancement of disease following
introduction of 300 median equid infectious doses of a
heterologous virus strain was reported following immu-
nization with a baculovirus-expressed recombinant sur-
face unit protein (rgp90) (Wang et al., 1994).
The potential for vaccine-induced enhancement of in-
fections by enveloped viruses has been documented in
both human and veterinary vaccine studies (Halsted,
1982; Porterfield, 1986; Vennema et al., 1990; Weiss and
Scott, 1981). In the case of AIDS vaccine research, there
has been considerable concern about the possibility of
immune enhancement of HIV-1 replication in target lym-
phocytes and macrophage cells (Bolognesi, 1989; Burke,
1992; Mascola et al., 1992; Montelaro and Bolognesi,
1995). Several studies have demonstrated that serum
antibodies from HIV-1-infected patients and SIV-infected
monkeys can mediate antibody-dependent enhance-
ment (ADE) of virus replication in defined in vitro assays
(Homsy et al., 1988; Montefiori et al., 1990a,b; Robinson
et al., 1988a), and limited studies have suggested that
the level of ADE may correlate with the progression of
disease (Homsy et al., 1990). However, the significance
of the observed in vitro ADE to the levels of in vivo virus
replication and disease severity remains uncertain and
controversial.
While the potential for AIDS vaccine enhancement has
focused primarily on baculovirus-expressed envelope
subunit vaccines (Dolin et al., 1991; Keefer et al., 1994;
McElrath et al., 1996; Robinson et al., 1988b), enhance-
ment has been reported with other viral envelope subunit
vaccines and DNA vaccines in EIAV and FIV vaccine
trials (Baldinotti et al., 1994; Hosie et al., 1992; Lombardi
et al., 1994; Richardson et al., 1997; Siebelink et al., 1995).
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Given the possible risk of enhancement with HIV-1 vac-
cines, and the absence of clear in vitro correlates of in
vivo enhancement, we continued to evaluate the EIAV
rgp90-induced enhancement in our well-established
pony model. We describe here two additional rgp90 vac-
cine trials which were conducted (i) to access the fre-
quency of immune enhancement of EIAV disease and
replication in a larger group of ponies, (ii) to conduct a
more critical analysis of this and previous rgp90 vacci-
nation data using a historical control panel of ponies for
comparison, (iii) to determine if enhancement of EIAV
replication and disease is associated with unique pa-
thologies, (iv) to better examine the possible correlation
of virus burden with enhanced clinical symptoms using
semiquantitative RT–PCR, and (v) to determine if the
antibodies elicited by the rgp90 vaccine affect the pro-
pensity for enhancement.
RESULTS
Response to virus challenge
All rgp90-vaccinated and control ponies were moni-
tored by standard AGID and ELISA assays of daily serum
samples to monitor seroconversion to EIAV p26 following
virus challenge. As expected, all ponies were seroneg-
ative to EIAV p26 on the day of challenge. After inocula-
tion with EIAVPV, all of the rgp90 II-immunized ponies
became seropositive at 21–23 days postinfection (dpi),
as observed with the control infections (data not shown).
Thus, the rgp90 vaccine failed to protect against EIAVPV
infection and did not alter the rate of p26 seroconversion.
The clinical responses of each control and vaccinated
pony were evaluated using several parameters, includ-
ing the time, severity, and number of febrile episodes, as
well as reductions in blood platelet levels. Clinical im-
pressions, the result of the daily observation of the ani-
mals for the presentation of sequelae characteristic of
equine infectious anemia, were also utilized in the eval-
uation of the disease experienced by the challenged
animals.
At the time of the rgp90 II vaccine trial, two naive
ponies were infected with 300 pony infectious doses of
our standard EIAVPV stock of virus to act as control
ponies. However, even in our established EIAV-pony sys-
tem using defined inoculations of EIAVPV, variation in
clinical disease has been observed. Therefore, to better
define the range of clinical responses that can be ex-
pected under the experimental infection circumstances
present in these vaccine trials, a panel of historical
controls was created. The clinical responses of the two
control ponies inoculated in this rgp90 II trial were com-
bined with those of eight additional ponies that had been
experimentally infected previously with the same stock
of EIAVPV (Table 1).
A total of 10 experimentally infected control animals
were examined. A febrile episode was defined as a
rectal temperature exceeding 39.4°C. The majority (8/10)
experienced their first febrile episodes at 17–21 dpi , with
a mean of 18.8 dpi. One pony (87) had its first fever at day
35 dpi, and two ponies (80 and 86) never experienced a
fever. Thrombocytopenia was defined as platelet num-
bers #105,000 platelets/ml of whole blood. Only 3/10
control ponies (564, 567, and 49) ever experienced clin-
ical thrombocytopenia. Of these 3, none experienced this
TABLE 1
Clinical Responses in Naive and rgp90-Immunized Ponies
Inoculated Intravenously with EIAVPV
Pony No.
First fever
(dpi)a
Platelet
decline (dpi)b
Clinical
responsec
Naive
80 None None Asymptomatic
86 None None Asymptomatic
98 21 None Moderate
06 19 None Moderate
561 17 None Moderate
562 17 None Moderate
564 18 34 Moderate
567 18 39 Moderate
87 35 None Moderate
49 18 36 Severe
Immunizedd
rgp90 I
1-5 13 ND Enhanced
1-6 15 ND Enhanced
1-7 11 ND Enhanced
21 13 ND Enhanced
rgp90 II
526 12 15 Enhanced
66 20 22 Enhanced
90 23 24 Enhanced
65 19 22 Enhanced
60 31 39 Moderate
120 37 41 Moderate
118 36 37 Moderate
64 37 None Moderate
56 None None Asymptomatic
rgp 90 III
616 18 18 Enhanced
675 35 38 Moderate
602 None None Asymptomatic
663 None None Asymptomatic
Multiple
immunizationse
46 10 13 Enhanced
119 11 17 Enhanced
63 40 40 Moderate
67 32 32 Moderate
a Day postinfection (dpi) of first febrile episode. Fever was defined as
a rectal temperature in excess of 39.4°C (103°F) and, if accompanied
by plasma viremia, was considered induced by EIAV.
b Thrombocytopenia was defined by platelet counts #105,000 per
microliter.
c Overall evaluation of disease severity based on clinical impres-
sions.
d Immunized ponies were challenged 24 days after their third dose of
immunogen (66 days after the first dose).
e Ponies 46 and 199 were challenged following a fourth immuniza-
tion. Ponies 63 and 67 were challenged following a fifth immunization.
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severe reduction in platelets prior to or during their first
febrile episode. Therefore, thrombocytopenia was ob-
served in only 30% of the control ponies, and it occurred
during or after the second febrile episode.
Based on the combined clinical parameters of fever,
thrombocytopenia, and clinical impressions, the overall
clinical responses of the control ponies were catego-
rized as asymptomatic, moderate, or severe. Of the 10
experimentally infected ponies evaluated here, 2 (80, 86)
did not experience fever or thrombocytopenia and were
characterized clinically as asymptomatic. Seven control
ponies (98, 06, 561, 562, 564, 567, and 87) experienced
fever and platelet drops that were considered moderate,
while 1 control pony (49) experienced clinical disease
signs so severe as to require euthanasia 43 days post-
challenge.
Using the above established historical range of EIA
clinical responses, we evaluated the nine ponies immu-
nized with rgp90 in the rgp90 II vaccine trial. The results
are listed in Table 1, while Fig. 1 summarizes the clinical
profiles of the rgp90 II-vaccinated ponies along with
those of the two rgp90 II control ponies for comparison.
Through daily observations, 4/9 of the vaccinated ponies
(526, 66, 90 and 65) experienced clinical signs deemed
to be more severe than those of the historical control
ponies. Only one of these four vaccinated ponies (526)
experienced a fever earlier than the controls (12 dpi).
However, unlike the controls, all four animals experi-
enced a severe decline in platelet numbers (#105,000/
ml), and these declines were closely associated with the
first febrile episode (12–23 dpi). The platelet numbers
observed for pony 65 rebounded somewhat at approxi-
mately 25 dpi but remained low. This animal was very ill
for the remainder of the vaccine trial. The progressive
clinical depression of ponies 526, 66, and 90 necessi-
tated humane euthanasia at days 26–43 postinfection.
Therefore, the presentation of thrombocytopenia associ-
ated with the first febrile episode, combined with severe
clinical impressions, led us to categorize the disease of
these four ponies as being enhanced.
Of the remaining five vaccinated ponies, four (120, 118,
64, and 60) experienced febrile episodes, but at some-
FIG. 1. Profiles of clinical responses in rgp90 II-vaccinated ponies and two naive ponies (49, 87) after EIAVPV challenge. Ponies were experimentally
infected with 103 TCID50 of EIAVPV at day 0 and observed for 45 days. Rectal temperature (closed squares, primary Y axis) and platelet counts per
ml of whole blood (open diamonds, secondary Y-axis) for each pony are indicated. Rectal temperatures in excess of 39.4°C were considered EIA
episodes only in conjunction with viremia and other characteristic clinical symptoms.
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what delayed time points (31–37 dpi) compared to
the control ponies (17–21 dpi). Although delayed,
this clinical response was not unusual, as control
pony 87 also experienced a later febrile episode (35
dpi). Immunized ponies 120, 188 and 60 experienced
severe declines in platelet numbers, while pony 64
did not. For ponies 120 and 118, these declines were
associated with the first febrile episode, but again
at a substantially later time point. Pony 60 experienced
its platelet drop concurrent with its second febrile
episode. Overall, the clinical impressions of these
four ponies fell within the range of those observed
for control ponies 98, 06, 561, 562, 564, 567 and
87. Therefore, these four vaccinated ponies were
characterized as clinically moderate; however, they
were representative of the less severe end of
the range of disease signs experienced by the con-
trols.
In contrast to the above eight ponies, the remaining
pony (56) remained asymptomatic for the entire 45-day
observation period; there was no detectable fever or
reduction in platelet numbers. However, as evidenced by
p26 seroconversion, this pony was determined to be
infected.
These data are in marked contrast to those reported
for the first rgp90 trial, in which all four vaccinates (100%)
experienced clinical disease signs more severe than
those experienced by the two control ponies in that trial.
When compared to the historical control panel (Table 1),
characterization of the rgp90 I vaccinates remains 100%
enhanced, thereby validating the data reported previ-
ously.
Pathology asociated with vaccine enhancement
To further characterize the severity of disease in the
rgp90 II vaccinates, necropsies were performed for
gross and microscopic pathology on representative po-
nies selected on the basis of outward signs of clinical
disease (three severe and two typical). Table 2 lists the
major pathological manifestations observed in the
rgp90-immunized ponies. Control pony 49, which expe-
rienced severe EIAV disease signs, is included for com-
parison. The circulatory lesions observed for pony 49
included petechial hemorrhages in the colon and small
intestine and splenic congestion. The normally fatty bone
marrow contained red areas indicating stimulation of
hematopoiesis. Inflammation of the periportal and lobu-
lar region of the liver (defined as hepatitis) was ob-
served, as was evidence of hepatocyte degeneration
in the liver and lymphocytic infiltrates in the liver and
kidney.
Immunized ponies 526 and 66 presented signs of
disease that were more severe than those observed in
the historical control ponies and were found to have
numerous and more severe pathological findings than
pony 49. Petechial hemorrhages in ponies 526 and 66
were observed not only in the small intestine and colon,
but also in the pleural surfaces of the lung, and the
mucosa of the tongue and lips. The hepatitis and hyper-
plasia of the bone marrow observed in pony 526 was
quite severe. Ponies 526 and 66 were both observed to
have iron-laden macrophages in their circulation (evi-
dence of erythrocyte degeneration) and hemosiderosis
of the liver. Also, pony 66 demonstrated an inability to
clot resulting from a platelet count of only 35,000/ml
TABLE 2
Pathologic Manifestations of EIAV Infection within Control and rgp90-Immunized Ponies
Pathological lesions
rgp90-immunized ponies
Control pony
(49)526a 66 90 60b 120
Circulatory
Petechial hemorrhages 111 111 2 2 2 11
Hemosiderophages 111 1 2 2 2 2
Splenic congestion 1 1 1 1 1 1
Inability to clot 2 111 2 2 2 2
Bone marrow
Hyperplasia of hematopoietic marrow 111 2 1 2 2 11
Liver
Hepatatis (nonsuppurative) 11 1 1 2 2 1
Hemosiderosis 111 1 1 2 2 2
Vacuolar degeneration of hepatocytes 1 1 1 1 2 1
Lymphocytic infiltrate 1 1 1 1 1 1
Kidney
Lymphocytic infiltrate 11 1 2 1 2 1
Brain
Lymphocytic infiltrate 11 2 2 2 2 2
a Ponies 526, 66, and 90 were observed to have enhanced clinical disease symptoms as defined in Table 1 and Fig. 1.
b Ponies 60 and 120 were observed to have moderate clinical disease symptoms as defined in Table 1 and Fig. 1.
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immediately before euthanasia, the lowest among all of
the ponies in this study. Pony 90 was also observed to
have severe clinical signs of an EIAV infection, however,
the lesions in this pony were less numerous than those
of ponies 526, 66 and even 49. Evidence of hepatitis in
the periportal and lobular regions of the liver and hemo-
siderosis were the major pathological findings in this
animal. Ponies 60 and 120 displayed moderate disease
signs, and upon necropsy, lymphocytic infiltrate and he-
patocyte degeneration in the liver were the only lesions
observed in these animals. These data suggest that
enhanced clinical disease was associated with severe
pathological changes in the rgp90 II vaccine trial. How-
ever, unique lesions were not observed in the vaccinated
ponies as compared to control pony 49.
Interestingly, ponies 526, 66, 90 and 49 experienced
severe clinical signs of disease; however, the observed
lesions in pony #90 were less severe than those of 526,
66 and 49. Ponies 526, 66, and 49 were euthanized at 26,
34, and 43 dpi, respectively, and all three were experi-
encing extremely severe febrile episodes at that time. In
contrast, pony 90 was euthanized at the conclusion of a
febrile episode (43 dpi). Also, ponies 60 and 120 were
found to have mild lesions upon necropsy and these
ponies were not experiencing a fever at the time of
euthanasia (43 dpi). Therefore, the clinical condition of
the ponies at the time of euthanasia seems to clearly
correlate with the number and severity of observed le-
sions.
Kinetics of virus replication
For this study, virus replication during the early stages
of the immune response was evaluated by detection of
infectious virus and measurements of viral RNA levels in
the plasma. The plasma viremia results for the rgp90-
vaccinated and historical control ponies are listed in
Table 3. Nine of the ten control ponies examined devel-
oped their first detectable plasma viremia at 11–13 dpi.
Pony 98 experienced its first plasma viremia somewhat
earlier, at 8 dpi. All control ponies remained positive for
plasma viremia for the remainder of the 21-day sampling
period. It is interesting to note that even though the
historical controls experienced signs of disease ranging
from asymptomatic to severe, their patterns of plasma
viremia were quite similar.
Of the rgp90-immunized ponies, the four that displayed
enhanced signs of disease (526, 90, 66, and 65) became
positive for plasma viremia at 10–13 dpi and remained
positive for the 21-day observation period. Thus, this
pattern of plasma viremia was similar to that observed in
the historical control ponies. The four immunized ponies
that experienced moderate signs of disease (120, 118,
64, and 60) were delayed in the appearance of detect-
able plasma viremia (20–37 dpi) compared to control
infections. Finally, the rgp90-immunized pony that was
asymptomatic during the observation period (56) was
plasma viremia negative for the entire observation pe-
riod. Taken together, the above plasma viremia data
failed to establish a definitive correlation between the
appearance of detectable plasma viremia and the ob-
served severity of EIA in the immunized ponies. These
data are in contrast to those reported for the first rgp90
vaccine trial, in which all four vaccinates (100%) had
more accelerated plasma viremia (7–9 dpi) than the EIA-
VPV-infected control ponies in that trial (Wang et al.,
1994). When compared to the historical control group,
these animals were still characterized as having en-
hanced levels of viremia.
To provide a more quantitative measure of EIAVPV
replication in the rgp90-immunized ponies, a semiquan-
titative RT–PCR assay was developed and used to mea-
sure EIAV-specific plasma RNA levels at 7, 14, and 21 dpi
(Table 3). At 7 dpi, only control pony 98 had a significant
level of viral RNA in plasma (105 molecules/ml). At 14 dpi,
the levels of detectable viral RNA in the control ponies
whose clinical signs were moderate or severe were
103–108 molecules/ml. The asymptomatic control ponies
(80 and 86) had levels below the accurate quantitative
limits of this assay (,102 molecules/ml). The mean value
of viral RNA in the controls at 14 dpi was 107 molecules/
ml. By 21 dpi, the viral RNA levels in the asymptomatic
controls remained the lowest with 103–104 molecules/ml,
while the remaining controls contained 105–107 mole-
cules/ml. The mean value of viral RNA at 21 dpi was 4 3
106 molecules/ml. Thus, the measurements of viral RNA
levels reveal differences in the levels of virus replication
in the historical control ponies that were not evident from
the measurement of plasma viremia. Control ponies that
were clinically asymptomatic clearly had lower levels of
viral RNA in plasma than did control ponies that experi-
enced moderate to severe disease signs.
Plasma collected from the rgp90 II-vaccinated ponies
at 7 dpi did not contain detectable levels of viral RNA. At
14 dpi, the levels of viral RNA in the rgp90 II vaccinates
that experienced enhanced disease signs were similar
to those of the controls. However, by 21 dpi, the viral RNA
levels in these vaccinates were on average 10-fold
higher than the historical controls (6x107 vs. 4 3 106
molecules/ml respectively). These data indicate that the
ponies that experienced enhanced disease had elevated
levels of virus replication compared to the historical
control ponies. The rgp90 II vaccinates that experienced
moderate clinical signs had lower levels of viral RNA at
14 and 21 dpi than the historical controls. Pony 56 re-
mained clinically asymptomatic for the duration of this
study and did not have detectable plasma viremia. How-
ever, low levels of viral RNA (102 molecules/ml) were
detected in the plasma of pony 56 at 14 and 21 dpi, thus
confirming the infection of this pony.
The viral RNA measurements presented here revealed
a definitive correlation between severity of disease and
levels of virus replication. Ponies experiencing enhanced
clinical disease had plasma RNA levels that were at 21
155EFFECTS OF rgp90 IMMUNIZATION
dpi an average of 10-fold greater than the plasma RNA
levels observed in the historical control ponies and 103-
fold higher compared to the group of immunized ponies
that experienced moderate disease. Vaccinated ponies
60, 120, 118, and 64 experienced less severe disease
and contained lower levels of viral RNA in plasma than
did the historical controls. Finally, viral RNA was de-
tected in the asymptomatic vaccinated pony (56), but at
lower levels than even the asymptomatic historical con-
trol ponies at 21 dpi.
For comparison, we used the semiquantitative RT–
PCR to assay the levels of EIAV RNA in plasma samples
taken from the four ponies (1-5, 1-6, 1-7, and 21) that were
immunized with rgp90 and challenged with EIAVPV in the
first vaccine trial (Wang et al., 1994). These data (Table 3)
indicate that the four vaccinated ponies had negligible
levels of viral RNA in plasma at 7 dpi, 106–108 mole-
cules/ml (mean value 7 3 107) at 14 dpi, and 105–108
molecules/ml (mean value 108) at 21 dpi. Thus, these
plasma RNA measurements were, on average, 10- to
100-fold higher than those of the historical control po-
nies. Taken together, characterization of the rgp90 I vac-
cinates as enhanced have been further validated by use
of RT–PCR.
Serological responses to the rgp90 vaccine and virus
challenge
As observed in the first rgp90 vaccine trial, serum
collected from the rgp90 II-vaccinated ponies immedi-
ately prior to challenge failed to neutralize the EIAVPV
challenge strain of virus (data not shown). The EIAV
TABLE 3
Kinetics of Virus Replication in rgp90-Vaccinated and Control Ponies Challenged with EIAVPV
Pony No.
Clinicala
status
Plasma viremia
First dayb Number of daysc
Viral RNA levels (molecules/ml)d
7 dpi 14 dpi 21 dpi
Naive
80 Asymptomatic 12 10 ,102e ,102 3 3 104
86 Asymptomatic 13 9 Negativef ,102 7 3 103
98 Moderate 8 14 2 3 105 1 3 108 1 3 107
6 Moderate 13 9 Negative 2 3 103 2 3 107
561 Moderate 11 11 ,102 2 3 106 2 3 106
562 Moderate 11 11 ,102 2 3 106 3 3 105
564 Moderate 12 10 ,102 8 3 105 2 3 106
567 Moderate 11 11 Negative 2 3 106 1 3 106
87 Moderate 13 9 Negative 4 3 103 2 3 105
49 Severe 11 10 Negative 4 3 103 5 3 105
rgp90 I
1-5 Enhanced 7 14 ,102 2 3 108 1 3 108
1-6 Enhanced 7 14 Negative 2 3 106 1 3 105
1-7 Enhanced 9 13 Negative 7 3 107 4 3 106
21 Enhanced 7 14 Negative 6 3 106 3 3 108
rgp90 II
526 Enhanced 11 11 Negative 2 3 107 2 3 107
66 Enhanced 13 9 Negative 2 3 105 2 3 108
90 Enhanced 10 12 Negative 2 3 104 2 3 107
65 Enhanced 10 10 Negative 1 3 105 2 3 107
60 Moderate 20 1 Negative ,102 6 3 103
64 Moderate 37 0 Negative 2 3 103 3 3 105
118 Moderate 36 0 Negative ,102 ,102
120 Moderate 20 1 Negative 3 3 104 3 3 102
56 Asymptomatic None 0 Negative ,102 9 3 102
rgp90 III
616 Enhanced 6 12 ,102 4 3 106 6 3 106
675 Moderate 18 4 Negative 2 3 102 2 3 103
602 Asymptomatic 18 2 ,102 3 3 102 5 3 103
665 Asymptomatic 11 4 Negative 7 3 102 ,102
a As described in Table 1.
b Plasma collected this day postinoculation (dpi) resulted in a positive RT result when incubated undiluted on fetal equine kidney cell cultures.
c Number of positive assays for plasma collected during the first 21 days postchallenge with EIAVPV.
d Viral RNA molecules/ml were calculated by semiquantitative RT–PCR. All numbers presented are the average of at least two independent assays.
e The lower limit of this assay was found to be 102 molecules/ml. If a viral RNA was detected for a sample in multiple assays, but the reuslting
quantitation was less than 102 molecules/ml, the sample was reported as ,102.
f If no viral RNA was detected in multiple assays, the sample was reported as negative.
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envelope-specific antibody response to rgp90 immuniza-
tion was further characterized in parallel by measure-
ment of antibody titers to viral glycoproteins (vgp) or to
the rgp90 protein by Con A ELISA using serum samples
taken on the day of challenge. As summarized in Fig. 2,
immunization with rgp90 in the second vaccine trial elic-
ited relatively high levels of antibodies to the vaccine
immunogen, with end point titers to rgp90 of 1/51,200 to
1/102,400 in all nine of the vaccinated ponies. In contrast,
the levels of serum antibody reactivity with the native
viral glycoproteins was on the average about 10-fold less
than that observed against the rgp90 vaccine antigen.
Serum end point titers with the viral glycoproteins ranged
from 1/3200 to 1/12,800 in the nine vaccine recipients.
Serological analyses of the rgp90 I and II vaccine
studies have demonstrated that the envelope-specific
antibodies elicited in both of these vaccine trials have
higher reactivity to the vaccine antigen than to native
viral envelope proteins. However, the antibody titers ob-
served in the rgp90 I vaccine trial were at least 10-fold
less than those observed in the rgp90 II trial (Fig. 2). Also,
4/4 (100%) of the rgp90 I vaccinates experienced en-
hanced disease compared to 4/9 (44%) of the rgp90 II
vaccinates. Based on the above serological data, we
hypothesized that low overall antibody titers may pro-
duce a more frequent enhancement of disease and that
the higher antibody titers in the second vaccine trial may
have resulted from modifications made in the pre-
paration of the protein immunogen (see Materials and
Methods).
Two approaches were taken to testing the above hy-
potheses. First, we attempted to determine if a more
rigorous immunization protocol with rgp90 would change
the properties of the antibody responses and, thereby,
the propensity for enhancement. Six ponies that had
received the standard three-dose rgp90 regimen in par-
allel with the nine immunized ponies described above
were administered one or two additional vaccine doses
for a total of four and five immunizations, respectively
(Table 4). As observed with the other rgp90-immunized
ponies, at 3 weeks following the third immunization an-
tibody reactivity to rgp90 was on average 10-fold greater
than that with vgp antigen (data not shown). Three
months following the third immunization with rgp90,
there was little difference in antibody reactivity titers to
the vaccine and vgp antigens. Two weeks following the
fourth and fifth immunizations, the serum reactivity to
rgp90 was on average 12- and 9-fold greater, respec-
FIG. 2. Reactivity of serum antibodies in rgp90-immunized ponies in Con A-ELISA. Serum samples were collected from the rgp90 I-, II-, and
III-vaccinated ponies immediately prior to challenge with EIAVPV. Con A-ELISA assays were conducted, as described under Materials and Methods,
testing serum antibody reactivity against the vaccine immunogen (rgp90; dark bars) and against viral envelope proteins (vgp; dotted bars). Results
are the average of at least two independent assays.
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tively, than that observed with vgp antigen. In general,
additional vaccine doses increased the antibody titer
and specificity for the rgp90 antigen compared to the
viral envelope proteins as ELISA substrates. These data
demonstrate that the specificity of serum antibodies elic-
ited by the rgp90 vaccine was, in fact, dependent on the
immunization regimen employed.
Three weeks after the fourth rgp90 immunization, po-
nies 46 and 119 were challenged with the standard
EIAVPV inoculum. Both ponies experienced early fevers
(10–11 dpi) concurrent with thrombocytopenia and were
characterized clinically as enhanced (Table 1). Ponies 63
and 67 were challenged in the same manner following
five immunizations. Fevers were documented at delayed
time points, 40 and 32 dpi, respectively, concurrent with
thrombocytopenia. Ponies 63 and 67 were categorized
as having moderate disease signs. Ponies 75 and 122
were not challenged. Therefore, the changes in antibody
specificity observed here did not alter the frequency of
vaccine enhancement in response to EIAV challenge.
rgp90 III vaccine trial
The second approach to evaluating the effect of the
immunogen on antibody levels, and ultimately the rela-
tionship between antibody levels and the frequency of
enhancement, was to conduct a third rgp90 vaccine trial
using protein immunogen that was prepared exactly as
in the rgp90 I vaccine trial. A total of four ponies were
immunized with rgp90 and challenged with EIAVPV as in
the rgp90 I and II vaccine trials. Using the clinical pa-
rameters described above, one pony (616) experienced
clinical signs of disease deemed more severe than the
historical control ponies (Table 1 and Fig. 3). This pony
experienced thrombocytopenia (platelets #105,000/ml)
concurrent with the first fever at 18 dpi. Pony 675 was
observed to have clinical disease signs similar to those
of the historical control ponies with fever and thrombo-
cytopenia experienced at a later time point (35 dpi).
Finally, two ponies (602 and 665) remained asymptom-
atic, having experienced neither a fever nor thrombocy-
topenia, for the duration of the study. These data are in
contrast to the rgp90 I and similar to the rgp90 II vaccine
trials in that a spectrum of disease states was observed.
Antibody titers to the vaccine and vgp antigens in the
rgp90 III-vaccinated ponies were measured by Con A
ELISA using serum collected on the day of challenge
(Fig. 2). As observed in the rgp90 I and II vaccinates,
levels of serum antibody reactivity to rgp90 in the rgp90
III vaccinates were on average 10-fold higher than that
observed with vgp. All four ponies had similar end point
titers of antibodies recognizing rgp90 (1/1600 to 1/3200)
and vgp (1/100 to 1/400). Furthermore, the overall levels
of serum antibody reactivity were similar to those ob-
served in the rgp90 I vaccine trial. These data clearly
demonstrated that the preparation of the rgp90 protein
immunogen can affect the overall levels of antibody elic-
ited by the vaccine. However, it would appear that lower
levels of antibody did not correlate with an increased
frequency of enhancement, as 100% enhancement was
observed in the rgp90 I vaccine trial, and 25% enhance-
ment was observed in the rgp90 III trial.
To complete the analysis of this third rgp90 vaccine
trial, levels of virus replication were evaluated in these
four ponies (Table 3). The pony that experienced en-
hanced disease (616) had detectable plasma viremia at
an earlier time point than the historical control ponies (6
dpi vs 8–13 dpi). Pony 616 was also found to have levels
of viral RNA somewhat higher than the mean value for
the historical control ponies at 21 dpi (6 3 106 mole-
cules/ml vs 3 3 106 molecules/ml). The pony that expe-
rienced moderate disease (675) and the two that re-
mained asymptomatic (602 and 665) had detectable
plasma viremia at time points similar to, and somewhat
more delayed than, the historical controls (11–18 dpi vs
8–13 dpi). Ponies 675, 602, and 665 also presented levels
of viral RNA that were at least 1000-fold lower than the
mean values for the historical controls at 21 dpi (102
molecules/ml vs 107 molecules/ml). Early detection of
plasma viremia and higher levels of viral RNA were
observed for the enhanced pony as compared to the
historical controls. Delayed detection of plasma viremia
and lower levels of viral RNA in plasma were observed
among the remaining three vaccinates which experi-
enced moderate and no disease signs. Overall, the data
accumulated for the rgp90 III vaccinates were similar to
TABLE 4
Antigen Specificity of Serum Antibodies after Sequential
Immunization of Ponies with EIAV rgp90
Pony No. ELISAa
Vaccine dose
Thirdb Fourth Fifth
46c rgp90 1:51200 .1:51200 Challenged
vgp 1:25600 1:3200
119 rgp90 1:12800 1:25600 Challenged
vgp 1:6400 1:1600
63d rgp90 1:51200 1:12800 1:12800
vgp 1:6400 1:1600 1:3200
67 rgp90 1:12800 1:12800 1:51200
vgp 1:25600 1:1600 1:6400
75e rgp90 1:6400 1:12800 1:25600
vgp 1:6400 1:1600 1:3200
122 rgp90 1:3200 1:25600 1:51200
vgp 1:6400 1:1600 1:3200
a Antibody reactivities to the immunogen and EIAV native envelope
glycoprotein were evaluated by ConA ELISA utilizing EIAV rgp90 and
Triton X-100-treated gradient purified EIAVPV, respectively.
b Serum samples were collected 3 months following the third immu-
nization. Other serum samples were evaluated 2 weeks following the
fourth and fifth immunizations.
c Ponies 46 and 119 were challenged following the fourth immuniza-
tion.
d Ponies 63 and 67 were challenged following the fifth immunization.
e Ponies 75 and 122 were not challenged.
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the rgp90 I and rgp90 II vaccinates in that a correlation
between disease severity and levels of virus replication
was observed.
Statistical analysis of the correlation of RNA levels
and disease severity
In the three separate rgp90 vaccine trials described
above, the frequency of enhanced signs of disease was
observed to be variable. To determine if a true statistical
correlation between levels of viral RNA and severity of
disease existed, the nonparametric, two-tailed Mann–
Whitney test was applied to all nine of the rgp90 vacci-
nated ponies that experienced enhanced disease (1-5,
1-6, 1-7, 21, 526, 66, 90, 65, 616) and to the historical
control panel. At 21 dpi, a value of P , 0.01 was derived.
Therefore, a statistically significant correlation between
levels of virus replication and severity of disease in the
rgp90 vaccinates characterized as clinically severe was
established.
DISCUSSION
When we first evaluated the baculovirus-expressed
EIAV rgp90 vaccine, we observed marked exacerbation
of EIAV disease and elevation of levels of viremia in 4 of
4 (100%) immunized ponies challenged with EIAVPV
(Wang et al., 1994). We describe here a comprehensive
study of the effects of this recombinant subunit vaccine.
Through the evaluation of a larger number of ponies (17
total in the rgp90 I, II, and III vaccine trials), and the use
of a historical control panel, these studies have verified
that the rgp90 vaccine uniformly fails to protect ponies
from infection by experimental challenge with EIAVPV.
The clinical responses observed after infection, however,
were not uniform. A total of 9 ponies (53%) vaccinated
with rgp90 experienced clinical signs of disease classi-
fied as more severe than those experienced by control
animals, 5 ponies (29%) were characterized clinically as
experiencing moderate signs of disease, and 3 vacci-
nated ponies (18%) remained asymptomatic for the du-
ration of the trials.
Following the clinical characterization of the ponies,
postmortem examinations and additional in vitro studies
were performed to further evaluate the animals. First, we
characterized the pathological changes associated with
enhanced disease. In general, ponies that were charac-
terized as enhanced were found to have more numerous
and severe lesions than control pony 49 (Table 2). In
addition, a clear association between the disease state
of the pony at the time of euthanasia and the severity of
lesions upon necropsy was established. However,
unique lesions in the rgp90-vaccinated ponies were not
observed. These observations suggest that the general
FIG. 3. Profiles of clinical responses in rgp90 III-vaccinated ponies after EIAVPV challenge. Ponies were experimentally infected with 10
3 TCID50 of
EIAVPV at day 0 and observed for 45 days. Rectal temperature (solid squares, primary Y-axis) and platelet counts/ml of whole blood (open diamonds,
secondary Y axis) for each pony are indicated. Rectal temperatures in excess of 39.40C were considered EIA episodes only in conjunction with
viremia.
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mechanisms of EIAV pathogenesis, while exacerbated,
were unaltered in the observed vaccine enhancement.
To determine if a correlation exists between clinical
disease and virus burden, the three rgp90 vaccine trials
were evaluated in combination. A definitive association
between severity of disease and plasma viremia was not
established in these studies. However, a definitive cor-
relation between severity of disease and levels of viral
RNA in plasma was established. Control ponies that
remained asymptomatic (80, 86) had lower viral RNA
levels at 14 and 21 dpi than controls that experienced
signs of disease. Vaccinated ponies with enhanced dis-
ease had on average 10-fold higher levels of viral RNA
than control ponies at 21 dpi. Vaccinated ponies with
moderate, but less severe, disease signs than the con-
trols had on average 100-fold less viral RNA at 21 dpi
than controls. Vaccinated ponies that remained asymp-
tomatic had levels of viral RNA equivalent to the asymp-
tomatic control ponies.
It is important to note here that even though severe
clinical disease in ponies has been correlated with high
levels of virus replication, the converse is not true. We
have observed a number of ponies that have experi-
enced extremely mild to no signs of disease that were
positive for plasma viremia and contained relatively high
levels of viral RNA in their plasma. For example, control
ponies 80 and 86 did not experience fever or thrombo-
cytopenia, but were found to be positive for plasma
viremia at 12–13 dpi and to contain 104 molecules of viral
RNA/ml of plasma at 21 dpi. These observations suggest
that high levels of virus replication are a necessary, but
insufficient, component of vaccine enhancement.
The exact mechanisms of the in vivo vaccine-induced
enhancement observed here are unknown. However, the
mechanism of antibody dependent enhancement in vitro
has been well established in other virus systems (Jolly et
al., 1989; Kliks et al., 1989; Olsen et al., 1992; Tamura et
al., 1994). An important area explored in these vaccine
trials was the relationship between the antibodies elic-
ited by the rgp90 immunogen and the frequency of en-
hancement. Several sets of data observed in these stud-
ies failed to establish a definitive association between
levels of serum antibody reactivity and enhancement of
disease. First, the rgp90 immunogens used in the rgp90
I and rgp90 II trials elicited much lower levels of antibody
than that observed in the rgp90 II trial, but enhancement
of disease in ponies was observed in all three trials.
Second, vaccine trials II and III displayed a spectrum of
disease states ranging from enhanced to asymptomatic,
in spite of the similar levels of serum antibody reactivity
within each group of ponies. Third, additional immuniza-
tions of rgp90 altered the serological properties of the
EIAV-specific antibodies, but did not affect the frequency
of enhancement after virus challenge.
It is known that the clinical presentation of EIAV
infections in the field is variable and can be classified
as acute, subacute, and even asymptomatic (Monte-
laro et al., 1993). In addition, we have described here
a historical control panel of 10 outbred ponies. Despite
being infected in a consistent manner, disease signs
ranging from severe to asymptomatic were observed.
Individual differences among outbred animals may be
the underlying basis for the range of frequencies of
enhancement observed in the three rgp90 vaccine
trials described here, i.e., 100, 44, and 25%. It is im-
portant to note, however, that in over 100 experimental
EIAVPV infections performed by this laboratory, dis-
ease signs as severe as those experienced by the
‘‘enhanced’’ rgp90 vaccinates have never been ob-
served. Therefore, the clinical signs of disease desig-
nated as enhanced in these studies appears to be the
direct result of rgp90 immunization.
At present, phase III clinical trials of HIV-1 vaccines
are not being conducted in the United States, at least in
part, because of concerns about the possibility that vac-
cinated individuals may be more susceptible to infection
or may experience enhanced disease symptoms upon
infection. The data presented here indicating a 53% in
vivo rate of enhancement of EIAV disease and virus
replication following vaccination with a baculovirus ex-
pressed recombinant envelope vaccine are relevant to
HIV-1 vaccine trials. The enhancement observed with the
rgp90 vaccine in the EIAV system is in distinct contrast to
the results reported for a baculovirus envelope subunit
vaccine in the SIV/rhesus macaque system (Ahmad et
al., 1994). In these vaccine trials, the baculovirus-ex-
pressed SIVmac239 gp160 vaccine failed to elicit protec-
tive immune responses, but did not appear to result in
enhancement of virus replication or disease. While one
might attribute the high rate of EIAV vaccine enhance-
ment to the exclusively macrophage-tropic nature of this
lentivirus, recent reports of vaccine enhancement in the
FIV system demonstrate the potential for vaccine en-
hancement of predominantly lymphotropic lentiviruses
(Hosie et al., 1992; Richardson et al., 1997; Siebelink et
al., 1995). Thus, the potential for enhancement with can-
didate HIV-1 vaccines should continue as a practical
consideration in all AIDS vaccine trials.
MATERIALS AND METHODS
Preparation of vaccine
For all vaccine trials discussed here, the prototype
cell-adapted strain of EIAV (EIAVPr) (Malmquist et al.,
1973) was used to generate the baculovirus EIAV env
recombinant (rgp90), as described in Wang et al.
(1994). The rgp90 proteins were expressed in and
extracted from baculovirus-infected SF9 cells as re-
ported previously (Wang et al., 1994). The recombinant
envelope proteins used in the rgp90 I and III vaccine
trials were solubilized in NP-40 buffer as described in
Wang et al. (1994). The rgp90 II immunogen was pre-
pared in 5% NP-40, 0.5% SDS, 0.5% Sarkosyl, and 8 M
urea to render the protein preparation more soluble.
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All rgp90 preparations were extracted, purified, ana-
lyzed, and quantitated as described previously (Wang
et al., 1994). Prior to use, the rgp90 preparations were
stored at 270°C until prepared with equal volumes of
adjuvant (Syntex Laboratories, Palo Alto, CA) to a final
concentration of 5 mg of threonylmuramyl dipeptide
(t-MDP)/2-ml dose of vaccine. Each immunization con-
tained a total of 200 mg of protein, calculated to con-
tain about 75 mg of rgp90.
Experimental immunization and virus challenge
procedures
For the rgp90 II and rgp90 III vaccine trials, 11 and 4
preconditioned grade ponies, respectively, were kept
and used per protocols approved by the University of
Kentucky Institutional Animal Care and Use Committee.
All principals were immunized with three injections of the
rgp90 preparations at 3-week intervals. All vaccinated
animals were then challenged intravenously with 300
median equid infectious doses of the heterologous EIA-
VPV strain of virus 24 days after their last immunization
(Lichtenstein et al., 1995). Two naive ponies (49 and 87)
were not immunized and were inoculated with EIAVPV in
parallel with the rgp90-vaccinated ponies. The clinical
responses of these two controls were compiled with
those of 8 additional ponies that were inoculated previ-
ously with the same virus stock. The clinical progression
of the 8 historical controls has been determined previ-
ously as part of other experimental infection and immu-
nization studies (Costa et al., 1994; Hammond et al., 1997;
McCoy, 1995). The ponies were held in box stalls, main-
tained on a diet of hay and oats, with trace mineral salt
blocks available ad libitum, and observed daily. Blood
samples collected prior to immunization and at weekly
intervals until challenge were tested for packed cell
volume and platelet determinations or held at 270°C
and 220°C for documentation of plasma virus and se-
rum antibody levels. Serum and plasma samples were
collected daily until anti-EIAV p26 antibodies were de-
tected. The body temperatures of ponies were monitored
per rectum daily. A fever was defined as a body temper-
ature in excess of 39.4°C and was considered induced
by EIAV if accompanied by positive plasma viremia.
Plasma samples for analysis of platelet counts and
packed cell volume determination were processed man-
ually using the Unopette system (Becton–Dickinson,
Rutherford, NJ) twice each week and during febrile epi-
sodes. Thrombocytopenia was defined as a platelet
count of #105,000 per microliter. The ponies were eu-
thanized with an overdose of phenobarbital solution in-
travenously at the termination of the experiment or if
severe clinical signs of EIA were observed and death
appeared imminent. Postmortem examinations were per-
formed on all ponies sacrificed before their projected
termination.
Measurements of virus replication
Plasma samples for determination of virus burden
were collected daily for the first 21 dpi and stored at
270°C. Plasma viremia was detected by infecting fetal
equine kidney cell cultures with 0.5 ml of plasma. Super-
natants from these cultures were collected after 4 weeks
of cultivation and tested for reverse transcriptase activity.
Additional plasma samples from rgp90-immunized and
control ponies were tested for the presence of viral RNA
using a semiquantitative RT–PCR assay using gag-gene
specific amplification primers (Lichtenstein et al., 1995).
Negative and positive controls were added at each step.
All samples were run in a minimum of two independent
assays.
Analysis of antibody responses
Anti-EIAV p26 antibodies present in serum samples
from the experimental animals were detected using the
agar gel immunodiffusion (AGID) and/or competitive en-
zyme-linked immunosorbence (CELISA) tests with com-
mercially available test reagents (Fermenta Animal
Health, Kansas City, MO) (Pearson and Coggins, 1979).
Antibodies against EIAV determinants were also identi-
fied using the immunoblot test (Rwambo et al., 1990) and
an ELISA assay using viral gp90 or rgp90 bound to
microtiterplates with ConA (Hammond et al., 1997).
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